Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders: 2015-2024
Historic Net Income towards Common Stockholders for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$318.8 million.
- Syndax Pharmaceuticals' Net Income towards Common Stockholders fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.8 million for FY2024, which is 52.25% down from last year.
- Syndax Pharmaceuticals' Net Income towards Common Stockholders amounted to -$318.8 million in FY2024, which was down 52.25% from -$209.4 million recorded in FY2023.
- In the past 5 years, Syndax Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $24.7 million in FY2021 and a low of -$318.8 million during FY2024.
- For the 3-year period, Syndax Pharmaceuticals' Net Income towards Common Stockholders averaged around -$225.8 million, with its median value being -$209.4 million (2023).
- Per our database at Business Quant, Syndax Pharmaceuticals' Net Income towards Common Stockholders surged by 133.90% in 2021 and then tumbled by 704.02% in 2022.
- Over the past 5 years, Syndax Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$72.9 million in 2020, then spiked by 133.90% to $24.7 million in 2021, then plummeted by 704.02% to -$149.3 million in 2022, then tumbled by 40.19% to -$209.4 million in 2023, then plummeted by 52.25% to -$318.8 million in 2024.